Table 1 Baseline demographics and clinical characteristics
Screen failed prior to DaT-SPECT collection | DaT-SPECT screened | DaT-SPECT “abnormal” | DaT-SPECT “normal” | |
|---|---|---|---|---|
N | 85 | 398 | 383 | 15 |
Male | 54 (63.5) | 280 (70.5) | 269 (70.4) | 11 (73.3) |
Caucasian | 75 (88.2) | 360 (90.7) | 348 (91.1) | 12 (80.0) |
Age at enrollment, y | 63.8 ± 9.73 | 60.0 ± 8.99 | 60.1 ± 9.00 | 58.6 ± 8.96 |
PD classification | ||||
TD | 53 (67.1) | 281 (70.8) | 273 (71.5) | 8 (53.3) |
PIGD | 22 (27.8) | 84 (21.2) | 79 (20.7) | 5 (33.3) |
Indeterminate | 4 (5.1) | 32 (8.1) | 30 (7.9) | 2 (13.3) |
Time since disease onset at enrollment, y | 2.5 ± 2.34 | 1.9 ± 1.76 | 1.9 ± 1.72 | 2.7 ± 2.69 |
Time since PD diagnosis, y | 0.6 ± 0.62 | 0.7 ± 0.64 | 0.7 ± 0.64 | 0.5 ± 0.59 |
Prior PD medication historya | 9 (10.6) | 70 (17.6) | 68 (17.8) | 2 (13.3) |
MDS-UPDRS score | ||||
Total (I + II + III) | 36.0 ± 16.73 | 32.3 ± 12.91 | 32.6 ± 12.91 | 24.9 ± 8.87 |
Part I | 5.4 ± 4.89 | 4.4 ± 3.61 | 4.4 ± 3.64 | 5.1 ± 2.81 |
Part II | 6.2 ± 4.93 | 5.3 ± 3.92 | 5.4 ± 3.95 | 3.7 ± 2.55 |
Part III | 24.4 ± 10.78 | 22.5 ± 9.12 | 22.8 ± 9.15 | 16.2 ± 5.53 |
Max UPDRS resting tremor | 1.1 ± 0.96 | 1.2 ± 0.99 | 1.2 ± 0.99 | 0.9 ± 0.88 |
Posture stability score (UPDRS 3.12) | 0.3 ± 0.72 | 0.1 ± 0.36 | 0.1 ± 0.37 | 0.0 ± 0.00 |
Hoehn and Yahr scale | ||||
1 | 18 (24.0) | 104 (26.3) | 96 (25.2) | 8 (53.3) |
1.5 | 5 (6.7) | 23 (5.8) | 22 (5.8) | 1 (6.7) |
2 | 38 (50.7) | 250 (63.1) | 244 (64.0) | 6 (40.0) |
2.5 | 10 (13.3) | 17 (4.3) | 17 (4.5) | 0 (0) |
3 | 4 (5.3) | 2 (0.5) | 2 (0.5) | 0 (0) |
S&E ADL score | 92.7 ± 6.81 | 92.2 ± 7.24 | 92.2 ± 7.30 | 92.7 ± 5.94 |
MoCA score | 25.6 ± 3.96 | 27.4 ± 1.87 | 27.4 ± 1.88 | 27.4 ± 1.88 |
PASE score | Not available | 168.3 ± 86.74 | 168.3 ± 86.74 | Not available |